epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-512, Phase III. Recruitment complete

Moderate to severe ulcerative colitis

WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.

Five leading KPIs warn whether recruitment will reach its target, with the screening funnel and the corrective actions that have evidence behind them.

KPIs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Will the plan work?

Feasibility stretch

24.2% of site capacity

On course Competing trials: A few

Sites open against plan

70 of 70 planned

On course The plan spreads each country's sites over its start-up window

First site open to first patient

1.3 months

On course Alert at 2.3 months

Is recruitment on course?

Enrolment against plan

471 of 502 expected

On course Patients randomised against the plan

Site rate against expectation

×0.93 of expected

On course All sites pooled

Will the plan work?

The plan needs 70 sites, 24.2% of what its countries can supply, against a few competing trials. That leaves room to add sites if recruitment falls behind.

Sites are opening on schedule

Sites openNumber, by month, against the plan spread over each country's start-up window

Show data
Sites open: planned and actual, by month
MonthPlannedActual
Sep 202100
Dec 202100
Mar 202298
Jun 20223335
Sep 20225456
Dec 20226464
Mar 20237070
Jun 20237070
Sep 20237070
Dec 20237070
Mar 20247070
Jun 20247070
Sep 20247070
Dec 20247070
Mar 20257070
Jun 20257070
Sep 20257070
Dec 20257070
Mar 20267070
Jun 20267070

Sources: epiClinical synthetic sites; start-up windows from the planner parameters (D25)

Overdue for a first patient: 5.7% of open sites

Open sites by countryMonths from activation to first patient; hollow dots have none yet; orange marks a wait longer than nine in ten similar sites, or none randomised despite three or more expected

Show data
Months from activation to first patient, by site
SiteCountryMonths to first patientFlagged
512-US-01, PhoenixUnited States0.2No
512-US-02, BaltimoreUnited StatesNone yet, 48.3 months openYes
512-US-03, MiamiUnited States2.6No
512-US-04, NashvilleUnited States0.6No
512-US-05, PhiladelphiaUnited States7.1No
512-US-06, BostonUnited States2.8No
512-US-07, HoustonUnited States0.5No
512-US-08, Salt Lake CityUnited States1.1No
512-US-09, New YorkUnited States20.6No
512-US-10, AtlantaUnited States5.6No
512-US-11, CharlotteUnited States34.6No
512-US-12, ClevelandUnited StatesNone yet, 47.5 months openYes
512-US-13, DallasUnited States9.1No
512-US-14, SeattleUnited States1.2No
512-US-15, DenverUnited States16.1No
512-US-16, ChicagoUnited States7.2No
512-US-17, Los AngelesUnited States11.3No
512-US-18, PittsburghUnited States8.5No
512-US-19, San DiegoUnited States22.4No
512-US-20, MinneapolisUnited States13.5No
512-UK-01, BristolUnited Kingdom10.1No
512-UK-02, SheffieldUnited Kingdom6.4No
512-UK-03, NewcastleUnited Kingdom7.3No
512-UK-04, LondonUnited Kingdom27.2No
512-UK-05, CardiffUnited Kingdom40.3No
512-UK-06, BirminghamUnited Kingdom1.9No
512-UK-07, LiverpoolUnited Kingdom34.9No
512-UK-08, SouthamptonUnited Kingdom18.4No
512-ES-01, BarcelonaSpain9.0No
512-ES-02, Santiago de CompostelaSpain4.5No
512-ES-03, SalamancaSpain5.8No
512-ES-04, SevilleSpain0.1No
512-ES-05, MurciaSpain2.3No
512-ES-06, PamplonaSpain0.4No
512-ES-07, BilbaoSpainNone yet, 49.3 months openYes
512-ES-08, AlicanteSpain7.8No
512-ES-09, ValenciaSpain7.0No
512-ES-10, GranadaSpain23.6No
512-PL-01, LublinPoland7.9No
512-PL-02, KatowicePoland11.3No
512-PL-03, RzeszówPoland6.0No
512-PL-04, ŁódźPoland3.0No
512-PL-05, WrocławPoland7.9No
512-PL-06, KrakówPoland3.3No
512-PL-07, BydgoszczPoland2.5No
512-PL-08, PoznańPoland10.9No
512-PL-09, OlsztynPoland0.8No
512-PL-10, WarsawPoland12.1No
512-PL-11, BiałystokPolandNone yet, 41.7 months openYes
512-PL-12, ZamośćPoland3.2No
512-PL-13, GdańskPoland5.2No
512-PL-14, SzczecinPoland1.4No
512-PL-15, LublinPoland0.2No
512-PL-16, KatowicePoland21.7No
512-TR-01, DiyarbakırTurkey3.3No
512-TR-02, AdanaTurkey3.5No
512-TR-03, AntakyaTurkey25.8No
512-TR-04, MalatyaTurkey2.4No
512-TR-05, BursaTurkey25.8No
512-TR-06, KayseriTurkey29.7No
512-TR-07, IstanbulTurkey13.1No
512-TR-08, AnkaraTurkey6.8No
512-IN-01, HyderabadIndia0.5No
512-IN-02, ChandigarhIndia7.6No
512-IN-03, KochiIndia7.9No
512-IN-04, VelloreIndia1.2No
512-IN-05, ChennaiIndia0.2No
512-IN-06, BengaluruIndia6.0No
512-IN-07, JaipurIndia0.1No
512-IN-08, BhubaneswarIndia25.5No

Source: epiClinical synthetic sites. A slow site can wait months for its first patient by design, so each is judged against its own expected rate. At study level, a first patient more than about 70 days after the first site opened predicted slow accrual (MD Anderson, 4,269 trials). That alert, 2.3 months, drives the scorecard. It is a cut-off from historical data, not a standard.

Is recruitment on course?

Recruitment is keeping pace

Patients randomisedCumulative, against the count the plan expects from each country's rate and opening window

Show data
Patients randomised: planned and actual, by month
MonthPlannedActual
Sep 202100
Dec 202100
Mar 202211
Jun 2022911
Sep 20222629
Dec 20225251
Mar 20238379
Jun 2023115116
Sep 2023147140
Dec 2023179167
Mar 2024212192
Jun 2024244219
Sep 2024276261
Dec 2024308292
Mar 2025341316
Jun 2025373351
Sep 2025405380
Dec 2025438415
Mar 2026470448
Jun 2026502471

Sources: epiClinical synthetic sites; plan from the planner. Studies under 60% of target at the planned end rarely recovered in NCI data (review note 02).

Which sites are behind their expectation?

Patients randomised as a share of those expectedEach dot a site, against the patients it was expected to recruit since it opened

Limits
Show data
Each site: patients expected to date, patients randomised and how far it is from its expectation
SiteCountryExpectedRandomisedObserved ÷ expectedJudgement
512-US-01, PhoenixUnited States3.310×2.988Within normal variation
512-US-02, BaltimoreUnited States4.30×0Within normal variation
512-US-03, MiamiUnited States5.710×1.741Within normal variation
512-US-04, NashvilleUnited States10.313×1.266Within normal variation
512-US-05, PhiladelphiaUnited States5.95×0.845Within normal variation
512-US-06, BostonUnited States4.23×0.721Within normal variation
512-US-07, HoustonUnited States9.86×0.61Within normal variation
512-US-08, Salt Lake CityUnited States8.611×1.275Within normal variation
512-US-09, New YorkUnited States8.57×0.819Within normal variation
512-US-10, AtlantaUnited States2.45×2.079Within normal variation
512-US-11, CharlotteUnited States4.42×0.454Within normal variation
512-US-12, ClevelandUnited States4.70×0Within normal variation
512-US-13, DallasUnited States6.62×0.302Within normal variation
512-US-14, SeattleUnited States5.69×1.613Within normal variation
512-US-15, DenverUnited States3.61×0.276Within normal variation
512-US-16, ChicagoUnited States8.012×1.502Within normal variation
512-US-17, Los AngelesUnited States3.13×0.982Within normal variation
512-US-18, PittsburghUnited States4.74×0.86Within normal variation
512-US-19, San DiegoUnited States5.52×0.364Within normal variation
512-US-20, MinneapolisUnited States5.13×0.583Within normal variation
512-UK-01, BristolUnited Kingdom3.54×1.152Within normal variation
512-UK-02, SheffieldUnited Kingdom6.82×0.295Within normal variation
512-UK-03, NewcastleUnited Kingdom9.85×0.509Within normal variation
512-UK-04, LondonUnited Kingdom8.42×0.238Within normal variation
512-UK-05, CardiffUnited Kingdom6.83×0.444Within normal variation
512-UK-06, BirminghamUnited Kingdom3.54×1.157Within normal variation
512-UK-07, LiverpoolUnited Kingdom5.92×0.338Within normal variation
512-UK-08, SouthamptonUnited Kingdom6.61×0.151Within normal variation
512-ES-01, BarcelonaSpain7.31×0.138Within normal variation
512-ES-02, Santiago de CompostelaSpain9.839×3.976Above the expected range
512-ES-03, SalamancaSpain7.27×0.969Within normal variation
512-ES-04, SevilleSpain9.95×0.503Within normal variation
512-ES-05, MurciaSpain7.04×0.572Within normal variation
512-ES-06, PamplonaSpain7.610×1.311Within normal variation
512-ES-07, BilbaoSpain5.80×0Within normal variation
512-ES-08, AlicanteSpain5.36×1.132Within normal variation
512-ES-09, ValenciaSpain5.47×1.287Within normal variation
512-ES-10, GranadaSpain5.43×0.556Within normal variation
512-PL-01, LublinPoland5.519×3.433Within normal variation
512-PL-02, KatowicePoland8.62×0.233Within normal variation
512-PL-03, RzeszówPoland5.52×0.365Within normal variation
512-PL-04, ŁódźPoland7.34×0.548Within normal variation
512-PL-05, WrocławPoland13.311×0.828Within normal variation
512-PL-06, KrakówPoland9.81×0.102Within normal variation
512-PL-07, BydgoszczPoland8.43×0.357Within normal variation
512-PL-08, PoznańPoland12.43×0.242Within normal variation
512-PL-09, OlsztynPoland16.98×0.473Within normal variation
512-PL-10, WarsawPoland9.91×0.101Within normal variation
512-PL-11, BiałystokPoland6.80×0Within normal variation
512-PL-12, ZamośćPoland6.84×0.585Within normal variation
512-PL-13, GdańskPoland9.18×0.88Within normal variation
512-PL-14, SzczecinPoland9.05×0.556Within normal variation
512-PL-15, LublinPoland7.513×1.735Within normal variation
512-PL-16, KatowicePoland9.63×0.311Within normal variation
512-TR-01, DiyarbakırTurkey6.41×0.157Within normal variation
512-TR-02, AdanaTurkey10.027×2.692Within normal variation
512-TR-03, AntakyaTurkey5.41×0.185Within normal variation
512-TR-04, MalatyaTurkey10.936×3.309Within normal variation
512-TR-05, BursaTurkey3.82×0.531Within normal variation
512-TR-06, KayseriTurkey7.11×0.142Within normal variation
512-TR-07, IstanbulTurkey6.13×0.495Within normal variation
512-TR-08, AnkaraTurkey7.918×2.272Within normal variation
512-IN-01, HyderabadIndia8.612×1.395Within normal variation
512-IN-02, ChandigarhIndia8.63×0.348Within normal variation
512-IN-03, KochiIndia8.15×0.616Within normal variation
512-IN-04, VelloreIndia10.59×0.86Within normal variation
512-IN-05, ChennaiIndia10.332×3.094Within normal variation
512-IN-06, BengaluruIndia8.710×1.151Within normal variation
512-IN-07, JaipurIndia6.110×1.629Within normal variation
512-IN-08, BhubaneswarIndia4.21×0.237Within normal variation

Source: epiClinical synthetic sites. Allowing for site spread (coefficient of variation 0.9), a site expected to recruit a handful of patients can recruit none and still be within normal variation. Poisson-only limits flag far more sites.

Pooled, no country or region is outside its range; Poland is furthest behind at ×0.59

Sites grouped by country and flagged regionPatients randomised as a share of those expected; the bar is where an ordinary group of that size would land

Show data
Each group: sites, patients randomised against expected, and the range ordinary groups of that size fall in
GroupSitesRandomisedExpectedObserved ÷ expectedOrdinary rangeJudgement
United States20108114.4×0.944×0.589 to ×1.507Within normal variation
United Kingdom82351.3×0.449×0.411 to ×1.817Within normal variation
Spain108270.7×1.159×0.474 to ×1.7Within normal variation
Poland1687146.5×0.594×0.568 to ×1.543Within normal variation
Turkey88957.5×1.548×0.417 to ×1.807Within normal variation
India88265.2×1.258×0.428 to ×1.787Within normal variation
2023 earthquake province46532.7×1.989×0.257 to ×2.179Within normal variation
Belarus border region106.8×0×0 to ×3.581Within normal variation
Syria border region115.4×0.185×0 to ×3.635Within normal variation
Ukraine border region43825.3×1.499×0.257 to ×2.166Within normal variation

Source: epiClinical synthetic sites

Where patients are lost before randomisation

Benchmarks for each step from referral to randomisation. Screen failure explains where patients are lost; on its own it does not predict whether a study reaches its target.

StepTypical conversionSource
Trial available at the patient's centre (cancer care)44.4% (100% minus 55.6% with no trial available)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible, among patients with a trial available (cancer care, derived)about 52% ((14.8 + 8.1) / 44.4). Note: the often-quoted 78.5% appears to be 100% minus 21.5%, a misreading because 21.5% is a share of all patientsUnger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible among screened (primary care trials)median 83% (IQR 40% to 100%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Eligible among screened (knee osteoarthritis trials)median 71.9%Koog et al., Archives of Rheumatology, https://archivesofrheumatology.org/full-text/650
Approached among eligible (one oncology trial)91%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Agreed among those offered a trial (cancer trials, 35 studies)about 55% (55.0% treatment, 55.3% cancer control)Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155
Agreed among approached (one oncology trial)40%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Consented and randomised among eligible (388 NIHR trials)median 72% (IQR 50% to 88%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Enrolled among eligible (primary care trials)median 74% (IQR 49% to 92%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Enrolled among all cancer patients (end to end)8.1% (15.9% academic, 7% community centres)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Screen failure after consent (oncology, one LMIC centre, 15 RCTs)51% failed (49% randomised); main causes inclusion criteria not met 54.9%, declined treatment 22.2%Parekh 2022, ecancermedicalscience, https://doi.org/10.3332/ecancer.2022.1476
Screen failure after consent (prodromal Alzheimer's, industry source)76% to 80% in two trials, against a typical 25% to 30% (grade D, not peer-reviewed)Worldwide Clinical Trials 2017 blog, https://www.worldwide.com/blog/2017/10/unique-4-step-approach-limits-high-screen-failure-in-alzheimers-disease-research-part-1/
Retained with valid primary outcome among randomised (388 NIHR trials)median 88% (IQR 80% to 97%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Recruitment rate (388 NIHR trials)median 0.95 participants per centre per month (IQR 0.42 to 2.60)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Consent to randomisation intervalno published benchmark found; protocol-specific, label any default Illustrativenone found

What works when a measure goes red

The evidence review's 16 corrective and preventive actions (CAPAs), strongest evidence first. Grade A is strong, D means no quantitative evidence was found.

ActionGradeAnswersEffect
Telephone follow-up of people who did not reply to an invitationAlow enrolment rate; low response to invitation lettersRisk difference +6 percentage points (95% CI 3 to 9), high certainty, clearest where baseline recruitment is low (under about 10% of those invited). Earlier version: RR 1.66 (95% CI 1.03 to 2.46), 2 studies, 1,058 participants.
Open rather than blinded placebo design (design stage only)Apredicted low enrolment at feasibility; high refusal linked to placeboRisk difference +10 percentage points (95% CI 7 to 13), high certainty.
Monetary thank-you for returning follow-up questionnairesBhigh drop-out; missing primary outcome data; low questionnaire returnPostal: RR 1.18 (95% CI 1.09 to 1.28); higher vs lower value RR 1.12 (1.04 to 1.22); electronic, offered on receipt, RR 1.25 (1.14 to 1.38). 2021 update: incentive vs usual follow-up RR 1.20 (1.06 to 1.36), 3 studies, 3,166 participants, low certainty.
Pre-notification before follow-up, with reward or reminderBhigh drop-out; low questionnaire returnMonetary reward with reminder or pre-notification improved retention, moderate certainty; no pooled number extracted. PROMETHEUS SWATs found pre-notification effective; no effect size in the abstract.
Reduce follow-up burden (home self-sampling, no extra diaries)Bhigh drop-out; missed visits; missing primary outcome dataSelf-sampling kits improved retention, moderate certainty (no pooled number extracted). Adding a diary reduced retention: RR 0.97 (95% CI 0.96 to 0.98), 2 studies, 9,906 participants, moderate certainty.
Opt-out contact for potential participantsClow enrolment rate; few patients approachedRR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update.
Personalised text messages for follow-upChigh drop-out; low questionnaire returnMixed: PROMETHEUS found personalised texts improved questionnaire response (no effect size in abstract); Cochrane pooled electronic reminders RR 1.01 (95% CI 0.95 to 1.09), 3 studies, 790 participants, low certainty.
Broaden eligibility criteria by protocol amendmentChigh screen failure; low eligible-to-screened ratio; low enrolment rateModelled in advanced NSCLC real-world data (61,094 patients): relaxing restrictive criteria more than doubled the eligible pool on average, with hazard ratio change of about 0.05 and no rise in toxicity-related discontinuation. No prospective evidence of the effect on actual randomisations. Amendments: median direct cost about $141k (phase II) and $535k (phase III), about 3 months added.
Participant payments or reimbursementClow consent among approached; low enrolment rateMixed in two RCTs: smoking-cessation trial consent 21.8% ($0) vs 35.9% ($200) vs 47.1% ($500); ambulation trial no effect (45.4%, 48.1%, 43.0%). No evidence of undue inducement in these low-risk trials.
Add decentralised elementsClow enrolment rate; high drop-out; patients living far from sitesOf 13 studies, 10 or 11 reported better recruitment with decentralised methods, mostly without head-to-head comparison; a 2022 systematic review found insufficient comparable data to say whether decentralised trials recruit or retain better.
Screening-log review to find the leaking funnel stageCany red recruitment KPI; high screen failure; low consent among approachedNo quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).
Close or replace non-enrolling sitesDsites with zero enrolment; low site productivity; slow activationNo quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data).
Add sites or countriesDlow enrolment rate; forecast misses last patient in dateNo quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.
Increase site or investigator paymentsDlow site productivity; low enrolment rateNo quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment.
Central campaigns, recruitment vendors and referral networksDfew patients identified; no trial available at local centres; low enrolment rateNo quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.
Site re-training and extra site support visitsDlow site productivity; low approach rate; high screen failure from avoidable errorsNo quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff.